cx-2009
mAbexperimentalImaging agent
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03149549)
Timeline
Indications
Mechanism of action
- CD166 antigenINHIBITOR
ALCAM inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- FM4
Oral
No
Parenteral
No
Topical
No
Also known as
- cx-2009
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04596150 | Phase 2 | Dec 15, 2020 | CytomX Therapeutics |
| NCT03149549 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | CytomX Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CytomX Therapeutics | For profit | 2 | 2 | 1 | 2017 |
1 organizations
Page 1 / 1